The glow stack (BPC-157, TB-500 and GHK-Cu): no study has tested it, and each component's human evidence used a different route

What it is. Three compounds injected together, usually sold pre-mixed: BPC-157, a synthetic fragment associated with gastric juice; TB-500, a fragment of the repair protein thymosin beta-4; and GHK-Cu, a copper-carrying tripeptide long used in skincare.

No study has tested the combination. Not the three together, and not any two of them for the purposes this stack is sold for.

Each component does have human research. That is the part worth checking, because the research is not in the form the stack uses. GHK-Cu's human studies are creams. The thymosin beta-4 human work is eye drops, intravenous infusions and a cardiac study. BPC-157's human record in this ledger is two people.

So the evidence people cite is real and it is about something else. A face cream's results do not become an injection's results by being quoted next to one.

None of the three is approved anywhere for the uses discussed here, and a pre-mixed blend has been assessed by no regulator.

One paper in this record's ledger names more than one of these compounds: a 2026 sports-medicine review whose stated aim was to summarize existing peer-reviewed data on 6 emerging peptides (BPC-157, thymosin beta-4 or TB-500, CJC-1295, MK-677, ipamorelin, and GHK-Cu [copper peptide]) for musculoskeletal recovery and enhancement in animal and human models.

That is a review listing them in the same article, not a study giving them together. No trial, no case series and no animal study has administered this combination.

The absence matters more here than for most stacks, because the three are marketed for a visible outcome. A claim about how skin looks after an injection is the kind of claim that is easy to test and has not been tested.

The receipts, in the studies' own words. A 2026 clinical review of the copper peptide in aesthetic medicine reports that clinically, GHK-Cu improved patient-reported satisfaction after laser resurfacing and significantly reduced wrinkle volume and depth compared with controls, and the 2006 randomised trial behind much of that reputation, which applied it to laser-resurfaced skin, found a significant difference in the posttreatment improvement of overall skin quality for patients using GHK-Cu. The thymosin beta-4 dry-eye trial reported statistically significant differences in both symptom and sign assessments, and its first-in-human study measured plasma concentrations after intravenous dosing, where the plasma concentration, maximum peak concentration and AUC of each dose group increased with the increase in the dose. BPC-157's human pilot study opens by noting that for years, the peptide Body Protection Compound 157 has been used to treat partial muscle or tendon tears, which is a statement about use rather than evidence.

Take the copper peptide first, because it carries most of the stack's promise. Its human results are genuine and repeatedly reported: better skin quality, reduced wrinkle volume and depth, improved scalp condition. Every one of those studies applied it to the skin. A cream reaches the tissue it is rubbed into at a concentration nobody has matched by injection, and no human study has injected it.

TB-500 is a second kind of mismatch. Most of the thymosin beta-4 literature is about the natural protein, studied as eye drops for dry eye and as an infusion, and the fragment sold as TB-500 is not identical to it. The human data belongs to the protein and the route belongs to the eye.

BPC-157 is the simplest case: the human record is two people and a field study, which the compound's own page sets out in full.

Each component's complete evidence is on its own record: GHK-Cu, TB-500 and BPC-157.

The reasoning is not arbitrary. The three are associated with different parts of tissue repair: BPC-157 with blood-vessel growth and tendon and gut healing in rodents, thymosin beta-4 with cell migration and actin regulation, and GHK-Cu with collagen synthesis and copper delivery. Three mechanisms, one process.

What that supports is a hypothesis. It is the same hypothesis a laboratory would test before selling it, and nobody has. Combining agents that act on different steps of one process can produce more effect, less effect or interference, and which one happens is an empirical question in every case.

The specific reason to be careful here is that the marketed outcome is cosmetic and fast. Rodent tendon healing and a collagen pathway are a long way from a change in how a face looks in eight weeks, and the studies that measured a change in how a face looks used a cream.

No published dose exists for this combination, so none appears here. Each component's own figures are on its record with the study that produced them, and each of those studies used a route this stack does not use, which is the reason they cannot simply be carried across.

The figures circulating for glow protocols come from clinics and vendors selling the blend. A pre-mixed vial also fixes the ratio between three compounds, a decision no study informed.

The honest summary is that each compound's safety record belongs to its route. GHK-Cu applied to skin has a long cosmetic safety history; that says nothing about injecting a copper-carrying peptide, and copper is an element the body regulates carefully. Thymosin beta-4 was tolerated in its eye and infusion studies. BPC-157's human safety record consists of the same two people as its efficacy record.

For the combination there is nothing, and the usual unknowns of a research-chemical blend apply: no regulator has assessed what is in the vial, no independent analysis of these blends is published, and three compounds in one solution raise questions of stability that nobody has answered publicly.

Discussed for: skin quality, hair, scars, recovery from training, and general repair, mostly by clinics and med spas and mostly to people over forty.

Studied in: for GHK-Cu, people using creams; for thymosin beta-4, people with dry eye and in pharmacokinetic studies; for BPC-157, rodents, and two people.

The unresolved questions are basic: whether any of the three reaches skin in a meaningful amount after subcutaneous injection, whether the copper peptide's topical results depend on local concentration that injection cannot reproduce, whether the fragment sold as TB-500 behaves like the protein its evidence belongs to, and whether three compounds in one vial remain what they were.

GHK-Cu is a cosmetic ingredient, sold openly in topical products; that is not an approval for injection. TB-500 and BPC-157 are unapproved and sold as research chemicals, and BPC-157 has been the subject of regulatory attention in compounding. A pre-mixed injectable blend of the three is not an approved product in any country.

All three are prohibited in sport under the categories covering peptide hormones, growth factors and related substances.

1. Citing GHK-Cu's skin studies for an injection. Every human study of it applied it topically.
2. Treating TB-500 and thymosin beta-4 as interchangeable. The human evidence belongs to the protein, and mostly to eye drops.
3. Reading BPC-157's rodent literature as human evidence. Its human record here is two people.
4. Assuming three mechanisms add up. Nobody has tested the combination, and combining agents can interfere as easily as it can help.
5. Taking a blend's ratio as a protocol. It is a manufacturing decision.
6. Expecting a visible result on the timescale of the marketing. The studies that measured visible change measured it after creams, over months.